Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Axalimogene Filolisbac in Cervical Cancer
NCT02164461Phase 1Completed
- Sponsor
- Advaxis, Inc.
- Start
- Mar 2015
- Primary completion
- Mar 2017
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of axalimogene filolisbac in Cervical Cancer (CC) (3 arms), sponsored by Advaxis, Inc. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 28 days, Listeria Monocytogenes Surveillance and 1 more. Started Mar 2015; status: completed.
02
Drugs
axalimogene filolisbac
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02164461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164461.